Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3

Alan W. Stitt, Ciara McGoldrick, Aine Rice-McCaldin, David R. McCance, Josephine V. Glenn, Daniel K. Hsu, Fu-Tong Liu, Suzanne R. Thorpe, Tom A. Gardiner

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Suppression of angiogenesis during diabetes is a recognized phenomenon but is less appreciated within the context of diabetic retinopathy. The current study has investigated regulation of retinal angiogenesis by diabetic serum and determined if advanced glycation end products (AGEs) could modulate this response, possibly via AGE-receptor interactions. A novel in vitro model of retinal angiogenesis was developed and the ability of diabetic sera to regulate this process was quantified. AGE-modified serum albumin was prepared according to a range of protocols, and these were also analyzed along with neutralization of the AGE receptors galectin-3 and RAGE. Retinal ischemia and neovascularization were also studied in a murine model of oxygen-induced proliferative retinopathy (OIR) in wild-type and galectin-3 knockout mice (ga13-/-) after perfusion of preformed AGEs. Serum from nondiabetic patients showed significantly more angiogenic potential than diabetic serum (P < 0.0001) and within the diabetic group, poor glycemic control resulted in more AGEs but less angiogenic potential than tight control (P < 0.01). AGE-modified albumin caused a dose-dependent inhibition of angiogenesis (P < 0.001), and AGE receptor neutralization significantly reversed the AGE-mediated suppression of angiogenesis (P < 0.01). AGE-treated wild-type mice showed a significant increase in inner retinal ischemia and a reduction in neovascularization compared with non-AGE controls (P < 0.001). However, ablation of galectin-3 abolished the AGE-mediated increase in retinal ischemia and restored the neovascular response to that seen in controls. The data suggest a significant suppression of angiogenesis by the retinal microvasculature during diabetes and implicate AGEs and AGE-receptor interactions in its causation.

Original languageEnglish (US)
Pages (from-to)785-794
Number of pages10
JournalDiabetes
Volume54
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Galectin 3
Advanced Glycosylation End Products
Ischemia
Serum
Retinal Neovascularization
Diabetic Retinopathy
Microvessels
Knockout Mice
Serum Albumin
Causality
Albumins
Perfusion
Oxygen
Advanced Glycosylation End Product-Specific Receptor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Stitt, A. W., McGoldrick, C., Rice-McCaldin, A., McCance, D. R., Glenn, J. V., Hsu, D. K., ... Gardiner, T. A. (2005). Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3. Diabetes, 54(3), 785-794. https://doi.org/10.2337/diabetes.54.3.785

Impaired retinal angiogenesis in diabetes : Role of advanced glycation end products and galectin-3. / Stitt, Alan W.; McGoldrick, Ciara; Rice-McCaldin, Aine; McCance, David R.; Glenn, Josephine V.; Hsu, Daniel K.; Liu, Fu-Tong; Thorpe, Suzanne R.; Gardiner, Tom A.

In: Diabetes, Vol. 54, No. 3, 03.2005, p. 785-794.

Research output: Contribution to journalArticle

Stitt, AW, McGoldrick, C, Rice-McCaldin, A, McCance, DR, Glenn, JV, Hsu, DK, Liu, F-T, Thorpe, SR & Gardiner, TA 2005, 'Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3', Diabetes, vol. 54, no. 3, pp. 785-794. https://doi.org/10.2337/diabetes.54.3.785
Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK et al. Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3. Diabetes. 2005 Mar;54(3):785-794. https://doi.org/10.2337/diabetes.54.3.785
Stitt, Alan W. ; McGoldrick, Ciara ; Rice-McCaldin, Aine ; McCance, David R. ; Glenn, Josephine V. ; Hsu, Daniel K. ; Liu, Fu-Tong ; Thorpe, Suzanne R. ; Gardiner, Tom A. / Impaired retinal angiogenesis in diabetes : Role of advanced glycation end products and galectin-3. In: Diabetes. 2005 ; Vol. 54, No. 3. pp. 785-794.
@article{2d9252df0cf043338b7c7942b02e4064,
title = "Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3",
abstract = "Suppression of angiogenesis during diabetes is a recognized phenomenon but is less appreciated within the context of diabetic retinopathy. The current study has investigated regulation of retinal angiogenesis by diabetic serum and determined if advanced glycation end products (AGEs) could modulate this response, possibly via AGE-receptor interactions. A novel in vitro model of retinal angiogenesis was developed and the ability of diabetic sera to regulate this process was quantified. AGE-modified serum albumin was prepared according to a range of protocols, and these were also analyzed along with neutralization of the AGE receptors galectin-3 and RAGE. Retinal ischemia and neovascularization were also studied in a murine model of oxygen-induced proliferative retinopathy (OIR) in wild-type and galectin-3 knockout mice (ga13-/-) after perfusion of preformed AGEs. Serum from nondiabetic patients showed significantly more angiogenic potential than diabetic serum (P < 0.0001) and within the diabetic group, poor glycemic control resulted in more AGEs but less angiogenic potential than tight control (P < 0.01). AGE-modified albumin caused a dose-dependent inhibition of angiogenesis (P < 0.001), and AGE receptor neutralization significantly reversed the AGE-mediated suppression of angiogenesis (P < 0.01). AGE-treated wild-type mice showed a significant increase in inner retinal ischemia and a reduction in neovascularization compared with non-AGE controls (P < 0.001). However, ablation of galectin-3 abolished the AGE-mediated increase in retinal ischemia and restored the neovascular response to that seen in controls. The data suggest a significant suppression of angiogenesis by the retinal microvasculature during diabetes and implicate AGEs and AGE-receptor interactions in its causation.",
author = "Stitt, {Alan W.} and Ciara McGoldrick and Aine Rice-McCaldin and McCance, {David R.} and Glenn, {Josephine V.} and Hsu, {Daniel K.} and Fu-Tong Liu and Thorpe, {Suzanne R.} and Gardiner, {Tom A.}",
year = "2005",
month = "3",
doi = "10.2337/diabetes.54.3.785",
language = "English (US)",
volume = "54",
pages = "785--794",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Impaired retinal angiogenesis in diabetes

T2 - Role of advanced glycation end products and galectin-3

AU - Stitt, Alan W.

AU - McGoldrick, Ciara

AU - Rice-McCaldin, Aine

AU - McCance, David R.

AU - Glenn, Josephine V.

AU - Hsu, Daniel K.

AU - Liu, Fu-Tong

AU - Thorpe, Suzanne R.

AU - Gardiner, Tom A.

PY - 2005/3

Y1 - 2005/3

N2 - Suppression of angiogenesis during diabetes is a recognized phenomenon but is less appreciated within the context of diabetic retinopathy. The current study has investigated regulation of retinal angiogenesis by diabetic serum and determined if advanced glycation end products (AGEs) could modulate this response, possibly via AGE-receptor interactions. A novel in vitro model of retinal angiogenesis was developed and the ability of diabetic sera to regulate this process was quantified. AGE-modified serum albumin was prepared according to a range of protocols, and these were also analyzed along with neutralization of the AGE receptors galectin-3 and RAGE. Retinal ischemia and neovascularization were also studied in a murine model of oxygen-induced proliferative retinopathy (OIR) in wild-type and galectin-3 knockout mice (ga13-/-) after perfusion of preformed AGEs. Serum from nondiabetic patients showed significantly more angiogenic potential than diabetic serum (P < 0.0001) and within the diabetic group, poor glycemic control resulted in more AGEs but less angiogenic potential than tight control (P < 0.01). AGE-modified albumin caused a dose-dependent inhibition of angiogenesis (P < 0.001), and AGE receptor neutralization significantly reversed the AGE-mediated suppression of angiogenesis (P < 0.01). AGE-treated wild-type mice showed a significant increase in inner retinal ischemia and a reduction in neovascularization compared with non-AGE controls (P < 0.001). However, ablation of galectin-3 abolished the AGE-mediated increase in retinal ischemia and restored the neovascular response to that seen in controls. The data suggest a significant suppression of angiogenesis by the retinal microvasculature during diabetes and implicate AGEs and AGE-receptor interactions in its causation.

AB - Suppression of angiogenesis during diabetes is a recognized phenomenon but is less appreciated within the context of diabetic retinopathy. The current study has investigated regulation of retinal angiogenesis by diabetic serum and determined if advanced glycation end products (AGEs) could modulate this response, possibly via AGE-receptor interactions. A novel in vitro model of retinal angiogenesis was developed and the ability of diabetic sera to regulate this process was quantified. AGE-modified serum albumin was prepared according to a range of protocols, and these were also analyzed along with neutralization of the AGE receptors galectin-3 and RAGE. Retinal ischemia and neovascularization were also studied in a murine model of oxygen-induced proliferative retinopathy (OIR) in wild-type and galectin-3 knockout mice (ga13-/-) after perfusion of preformed AGEs. Serum from nondiabetic patients showed significantly more angiogenic potential than diabetic serum (P < 0.0001) and within the diabetic group, poor glycemic control resulted in more AGEs but less angiogenic potential than tight control (P < 0.01). AGE-modified albumin caused a dose-dependent inhibition of angiogenesis (P < 0.001), and AGE receptor neutralization significantly reversed the AGE-mediated suppression of angiogenesis (P < 0.01). AGE-treated wild-type mice showed a significant increase in inner retinal ischemia and a reduction in neovascularization compared with non-AGE controls (P < 0.001). However, ablation of galectin-3 abolished the AGE-mediated increase in retinal ischemia and restored the neovascular response to that seen in controls. The data suggest a significant suppression of angiogenesis by the retinal microvasculature during diabetes and implicate AGEs and AGE-receptor interactions in its causation.

UR - http://www.scopus.com/inward/record.url?scp=14644435056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644435056&partnerID=8YFLogxK

U2 - 10.2337/diabetes.54.3.785

DO - 10.2337/diabetes.54.3.785

M3 - Article

C2 - 15734857

AN - SCOPUS:14644435056

VL - 54

SP - 785

EP - 794

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -